Convatec GroupLSE:CTEC +0.56%77 ROC (Joel Greenblatt) % is 24.55% as of Dec. 2025, which is 23% below its 10-year median of 32.00. GuruFocus rates LSE:CTEC with a GF Score™ of 77/100 and a GF Value™ of £2.56 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 839 Medical Devices & Instruments companies, Convatec Group ranks better than 79.86% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Convatec Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 24.55%.
The historical rank and industry rank for Convatec Group's ROC (Joel Greenblatt) % or its related term are showing as below:
LSE:CTEC'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 12.92 Med: 32 Max: 42.31
Current: 30.14
During the past 13 years, Convatec Group's highest ROC (Joel Greenblatt) % was 42.31%. The lowest was 12.92%. And the median was 32.00%.
LSE:CTEC's ROC (Joel Greenblatt) % is ranked better than 79.86% of 839
companies
in the Medical Devices & Instruments industry
Industry Median: 3.94
vs LSE:CTEC: 30.14
Convatec Group's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 2.10% per year.
Convatec Group (LSE:CTEC) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Convatec Group ROC (Joel Greenblatt) % Related Terms
Convatec Group ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Convatec Group's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:CTEC vs ISRG, BDX, MDLN: ROC (Joel Greenblatt) % Comparison
For the Medical Instruments & Supplies subindustry, Convatec Group's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Convatec Group ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Convatec Group's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Convatec Group's ROC (Joel Greenblatt) % falls into.
Convatec Group ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 24.55% mean?
Convatec Group (LSE:CTEC) has a ROC (Joel Greenblatt) % of 24.55% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Convatec Group and its competitors. This is 23% below median its historical median of 32.00. Over the past decade, Convatec Group's ROC (Joel Greenblatt) % has ranged from 12.92 to 42.31. According to the industry distribution chart, Convatec Group ranks #169 out of 839 companies in the Medical Devices & Instruments industry, placing it in the top 20.1%.
Is Convatec Group's ROC (Joel Greenblatt) % too high?
Convatec Group's current ROC (Joel Greenblatt) % of 24.55% is 23% below median its 10-year median of 32.00. Over the past 10 years, this metric has ranged from a low of 12.92 to a high of 42.31. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 3.94. Convatec Group's value of 24.55% is 523.1% above this industry median. Based on the distribution chart, Convatec Group ranks #169 out of 839 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Convatec Group has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Convatec Group's ROC (Joel Greenblatt) % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Convatec Group ranks #169 out of 839 companies for ROC (Joel Greenblatt) %. This places Convatec Group in the top 20% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 3.94. Convatec Group's value of 24.55% is 523.1% above this benchmark. Historically, Convatec Group's own ROC (Joel Greenblatt) % has ranged from 12.92 to 42.31 over the past decade. While the company's 10-year median is 32.00 vs. the industry median of 3.94, Convatec Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 3.94, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Convatec Group's current ROC (Joel Greenblatt) % of 24.55% is 523.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Convatec Group and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 3.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Convatec Group's current ROC (Joel Greenblatt) % is 24.55%, which is 23% below median its own 10-year median of 32.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Convatec Group stock overvalued right now?
Based on GuruFocus' analysis, Convatec Group (LSE:CTEC) is currently considered Modestly Undervalued. The stock's GF Value™ is £2.56, compared to a current price of £2.14 — trading 16.3% below its estimated fair value. The current ROC (Joel Greenblatt) % is 24.55%, which is 23% below median its 10-year median of 32.00 and 523.1% above the Medical Devices & Instruments industry median of 3.94. Convatec Group's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Convatec Group (LSE:CTEC), the current ROC (Joel Greenblatt) % is 24.55% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Convatec Group (LSE:CTEC) Overvalued in 2026?
Based on GuruFocus' analysis, Convatec Group stock appears to be undervalued.
The current stock price of £2.14 is trading 16.3% below its estimated GF Value™ of £2.56.
GuruFocus considers Convatec Group to be Modestly Undervalued.
Key valuation signals for LSE:CTEC:
ROC (Joel Greenblatt) %: 24.55% (23% below median its 10-year median of 32.00)
GF Value™: £2.56 vs. price of £2.14 (16.3% below fair value)
Industry Position: 523.1% above the Medical Devices & Instruments median (#169 of 839)
No single metric tells the full story. See the LSE:CTEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
77GF Score
Get the complete analysis for LSE:CTEC
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:CTEC has been successfully added to your 
